Nearly 10 million people in the United States and Europe are at high risk of developing liver cancer. This growing number of individuals is primarily comprised of patients with cirrhosis (scarring of the liver), which has various causes, such as obesity leading to
Early detection of liver cancer enables access to curative treatments such as ablation, resection, and transplants. Clinical best practice is for high risk patients to undergo biannual screening using ultrasound; however, the results are often insufficiently sensitive to detect early-stage cancers.
Mursla Bio is conducting a clinical study involving approximately 500 patients to validate a novel in vitro diagnostic (IVD) test to meet this clinical need.
Cells within organs, including the liver, continually secrete tiny membrane-bound particles known as Extracellular Vesicles (EVs). These EVs are packed with various biological molecules such as DNA, RNA, proteins, lipids, and metabolites, offering a real-time glimpse into the health of the originating cell.
Some of these EVs manage to navigate through the extracellular matrix—the complex network of proteins and sugars outside cells—and enter the bloodstream. Once in the circulation, they carry essential information from cell to cell, as well as between different tissues and organs.
When a blood sample is taken, it contains billions of these EVs and hundreds of thousands are derived from vital organs like the liver.
Mursla Bio's cutting-edge technology analyses rare, tissue-specific EVs in blood, such as those originating from the liver, with unmatched precision. This enables non-invasive tissue biopsy of a patient at any time, detecting disease biosignatures, like cancer, at their onset or recurrence.
This breakthrough is made possible by our AI-empowered biomarker discovery platform,
Our approach is not only specific but also extends across multiple 'omics' such as RNA, protein and glycan,
